Global market share of top pharma companies by anti-diabetic revenue 2017 and 2024
This statistic depicts the top ten pharmaceutical companies worldwide based on the global anti-diabetic revenue market share in 2017 and a projection for 2024. In 2017, Merck & Co accounted for some 12.8 percent of the global market for anti-diabetics, and is expected to decrease to some 5.3 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.
